JP2015509537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509537A5 JP2015509537A5 JP2014561048A JP2014561048A JP2015509537A5 JP 2015509537 A5 JP2015509537 A5 JP 2015509537A5 JP 2014561048 A JP2014561048 A JP 2014561048A JP 2014561048 A JP2014561048 A JP 2014561048A JP 2015509537 A5 JP2015509537 A5 JP 2015509537A5
- Authority
- JP
- Japan
- Prior art keywords
- polymorph
- degrees
- item
- theta
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 17
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 claims description 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- -1 1- (9H-purin-6-ylamino) propyl Chemical group 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- VDULOAUXSMYUMG-UHFFFAOYSA-N 2-phenyl-1h-quinazolin-4-one Chemical compound N=1C2=CC=CC=C2C(O)=NC=1C1=CC=CC=C1 VDULOAUXSMYUMG-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606870P | 2012-03-05 | 2012-03-05 | |
| US61/606,870 | 2012-03-05 | ||
| PCT/US2013/029157 WO2013134288A1 (en) | 2012-03-05 | 2013-03-05 | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016042418A Division JP2016104823A (ja) | 2012-03-05 | 2016-03-04 | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの多形性形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509537A JP2015509537A (ja) | 2015-03-30 |
| JP2015509537A5 true JP2015509537A5 (enExample) | 2016-04-21 |
Family
ID=49117265
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561048A Withdrawn JP2015509537A (ja) | 2012-03-05 | 2013-03-05 | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの多形性形態 |
| JP2016042418A Pending JP2016104823A (ja) | 2012-03-05 | 2016-03-04 | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの多形性形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016042418A Pending JP2016104823A (ja) | 2012-03-05 | 2016-03-04 | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの多形性形態 |
Country Status (31)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2015014315A1 (zh) * | 2013-08-01 | 2015-02-05 | 杭州普晒医药科技有限公司 | 一种抑制剂的晶型及其制备方法和用途 |
| US20160244452A1 (en) * | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015092810A2 (en) | 2013-11-20 | 2015-06-25 | Cadila Healthcare Limited | Amorphous form of idelalisib |
| WO2015095605A1 (en) * | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
| EA201690990A1 (ru) | 2013-12-20 | 2016-11-30 | Джилид Калистога Ллс | Способы получения ингибиторов фосфатидилинозитол-3-киназы |
| EP2979692A1 (en) | 2014-07-30 | 2016-02-03 | Sandoz Ag | Dosage form comprising a pressure sensitive solid form of an active pharmaceutical ingredient |
| EP3031808B1 (en) * | 2014-12-09 | 2018-06-27 | ratiopharm GmbH | Salt of idelalisib |
| WO2016097314A1 (en) * | 2014-12-19 | 2016-06-23 | Sandoz Ag | Amorphous and crystalline forms of idelalisib and process for forming the same |
| EP3048104A1 (en) | 2015-01-20 | 2016-07-27 | Sandoz AG | Amorphous and crystalline forms of idelalisib and process for forming the same |
| US20180064714A1 (en) * | 2015-03-13 | 2018-03-08 | Mylan Laboratories Ltd | Process for the Preparation of Amorphous Idelalisib and its Premix |
| CN106146501A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 一种无定型激酶抑制剂的制备方法 |
| CN106146500A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法 |
| WO2016157136A1 (en) | 2015-04-02 | 2016-10-06 | Mylan Laboratories Ltd | Crystalline forms of idelalisib |
| CN104892612B (zh) * | 2015-04-15 | 2017-12-19 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
| CN106146503A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | 一种Idelalisib的制备方法 |
| CZ2015347A3 (cs) | 2015-05-22 | 2016-11-30 | Zentiva, K.S. | Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava |
| CN106279171A (zh) * | 2015-06-09 | 2017-01-04 | 南京安源生物医药科技有限公司 | 一种Idelalisib的制备方法 |
| JP6522807B2 (ja) | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
| AU2016287463B2 (en) | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2017009333A1 (en) * | 2015-07-13 | 2017-01-19 | Synthon B.V. | Method for purifying idelalisib |
| IL257345B2 (en) | 2015-08-21 | 2023-03-01 | Morphosys Ag | Combinations and their uses |
| CZ2015575A3 (cs) * | 2015-08-26 | 2017-03-08 | Zentiva, K.S. | Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava |
| CN106565716B (zh) * | 2015-10-10 | 2021-06-15 | 上海创诺制药有限公司 | 一种Idelalisib晶型A及其制备方法 |
| HU231016B1 (hu) * | 2015-11-30 | 2019-11-28 | Egis Gyógyszergyár Zrt. | Idelalisib új polimorf és szolvát formája |
| WO2017175184A1 (en) * | 2016-04-07 | 2017-10-12 | Laurus Labs Limited | Process for preparation of amorphous form of idelalisib |
| EP3272348A1 (en) | 2016-07-21 | 2018-01-24 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising idelalisib |
| CN106632337B (zh) * | 2016-10-18 | 2018-11-20 | 湖北生物医药产业技术研究院有限公司 | 艾代拉里斯的晶型、药物组合物、制备方法和用途 |
| WO2018198131A1 (en) | 2017-04-24 | 2018-11-01 | Natco Pharma Limited | Process for the preparation of amorphous idelalisib |
| CN107573345B (zh) * | 2017-09-12 | 2020-01-10 | 浙江乐普药业股份有限公司 | 一种艾代拉利司及其中间体的制备方法 |
| CN109575027A (zh) * | 2017-09-29 | 2019-04-05 | 宁波爱诺医药科技有限公司 | 一种抗肿瘤药物艾德力布的一水合物及其制备方法 |
| WO2019178596A1 (en) | 2018-03-16 | 2019-09-19 | Johnson Matthey Public Limited Company | Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation |
| AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| GB202109006D0 (en) | 2021-06-23 | 2021-08-04 | Anglo American Minerio De Ferro Brasil S/A | Method of and system for operating a grinding mill |
| CN116410195B (zh) * | 2021-12-31 | 2025-07-18 | 同润生物医药(上海)有限公司 | 一种己二酸盐结晶及其制备方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1053063A (enExample) | 1963-05-18 | |||
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
| NL7204972A (enExample) | 1971-04-21 | 1972-10-24 | ||
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| DE2644265C2 (de) | 1976-09-30 | 1983-02-10 | Bayer Ag, 5090 Leverkusen | Chinazoline |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| DE2812635A1 (de) | 1978-03-22 | 1979-09-27 | Bayer Ag | Heterocyclische verbindungen |
| JPS55118917A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
| JPS55118918A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| JPS6017375B2 (ja) | 1979-06-20 | 1985-05-02 | 三菱電機株式会社 | ポリアミド樹脂の製造方法 |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| SG43072A1 (en) | 1991-06-18 | 1997-10-17 | American Home Prod | Method of treating adult t-cell leukemia/lymphoma |
| CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| FI951367A7 (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| EP1157698A3 (en) | 1994-08-12 | 2002-05-02 | Pro-Neuron, Inc. | Treatment of inflammatory diseases with oxypurine nucleosides |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| ATE242232T1 (de) | 1996-05-15 | 2003-06-15 | Pfizer | 2,3,6-trisubstituierte 4(3h)-chinazolinone |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| IL127296A (en) | 1996-12-31 | 2003-01-12 | Reddy Research Foundation | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| WO1998038173A1 (en) | 1997-02-28 | 1998-09-03 | Pfizer Products Inc. | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| EP0884310B1 (en) | 1997-06-09 | 2005-09-07 | Pfizer Products Inc. | Quinazolin-4-one ampa antagonists |
| WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
| IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
| EP1044004A1 (en) | 1998-01-08 | 2000-10-18 | The University Of Virginia Patent Foundation | A2a adenosine receptor agonists in combination with a type iv phosphodiesterase inhibitors |
| CN1208326C (zh) | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物 |
| US6048970A (en) | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
| US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
| US6046049A (en) | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
| IL149164A0 (en) | 1999-10-27 | 2002-11-10 | Cytokinetics Inc | Methods and compositions utilizing quinazolinones |
| BR0107456A (pt) * | 2000-01-07 | 2002-10-08 | Transform Pharmaceuticals Inc | Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse |
| ATE551325T1 (de) | 2000-01-24 | 2012-04-15 | Astrazeneca Ab | Therapeutische morpholino-substituierte verbindungen |
| EP1268472B1 (en) | 2000-02-07 | 2004-10-13 | Bristol-Myers Squibb Company | 3-aminopyrazole inhibitors of cyclin dependent kinases |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| EA008241B1 (ru) | 2000-04-25 | 2007-04-27 | Айкос Корпорейшн | Ингибиторы фосфатидилинозитол-3-киназы дельта человека |
| US7026330B2 (en) | 2002-05-30 | 2006-04-11 | The Children's Hospital Of Philadelphia | Methods for treatment of acute lymphocytic leukemia |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
| GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| CA2400254A1 (en) | 2002-09-19 | 2004-03-19 | University Health Network | Compositions and methods for treating heart disease |
| SI1549652T1 (sl) | 2002-09-30 | 2009-04-30 | Bayer Healthcare Ag | Kondenzirani azolpirimidinski derivati |
| CA2508601A1 (en) | 2002-12-06 | 2004-06-24 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
| BR0317572A (pt) | 2002-12-20 | 2005-11-22 | Warner Lambert Co | Benzoxazinas e seus derivados como inibidores de pi3ks |
| NZ542475A (en) | 2003-04-03 | 2009-04-30 | Semafore Pharmaceuticals Inc | PI-3 kinase inhibitor prodrugs |
| EP1644360A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | 3-substituted indoles and derivatives thereof as therapeutic agents |
| MXPA05012953A (es) | 2003-06-05 | 2006-02-13 | Warner Lambert Co | Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos. |
| EP1644364A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents |
| MXPA05013061A (es) | 2003-06-05 | 2006-03-02 | Warner Lambert Co | Benzotiofenos sustituidos con cicloalquilos y heterocicloalquilos como agentes terapeuticos. |
| WO2004108714A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkylsulfanyl substituted benzo[b]thiophenes as therapeutic agents |
| US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
| WO2005016349A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methods of inhibiting leukocyte accumulation |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| WO2005117889A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic |
| CN101123968A (zh) | 2004-06-04 | 2008-02-13 | 艾科斯有限公司 | 肥大细胞病的治疗方法 |
| US20080287469A1 (en) | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
| US20090131512A1 (en) | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
| CA2743642C (en) * | 2008-11-13 | 2017-09-19 | Calistoga Pharmaceuticals, Inc. | Therapies for hematologic malignancies |
| AU2009322187B2 (en) | 2008-12-04 | 2015-02-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders |
| EP2379510B1 (en) | 2008-12-24 | 2016-10-26 | Prana Biotechnology Ltd | Quinazolinone compounds |
| JP2012521994A (ja) | 2009-03-24 | 2012-09-20 | ギリアード カリストガ エルエルシー | ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法 |
| CA2759724A1 (en) | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals, Inc. | Methods of treatment for solid tumors |
| US20110230465A1 (en) | 2009-09-18 | 2011-09-22 | Boehringer Ingleheim International Gmbh | Viral polymerase inhibitors |
| CA2802484A1 (en) * | 2010-06-11 | 2011-12-15 | Gilead Calistoga Llc | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
| US20130143902A1 (en) * | 2011-12-02 | 2013-06-06 | Gilead Calistoga Llc | Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
| WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
-
2013
- 2013-03-05 BR BR112014021935A patent/BR112014021935A2/pt not_active IP Right Cessation
- 2013-03-05 CN CN201380011784.1A patent/CN104334560A/zh active Pending
- 2013-03-05 AP AP2014007875A patent/AP2014007875A0/xx unknown
- 2013-03-05 JP JP2014561048A patent/JP2015509537A/ja not_active Withdrawn
- 2013-03-05 PE PE2014001310A patent/PE20141792A1/es not_active Application Discontinuation
- 2013-03-05 UY UY0001034656A patent/UY34656A/es not_active Application Discontinuation
- 2013-03-05 MX MX2014010656A patent/MX2014010656A/es unknown
- 2013-03-05 AU AU2013203620A patent/AU2013203620B2/en active Active
- 2013-03-05 IN IN7105DEN2014 patent/IN2014DN07105A/en unknown
- 2013-03-05 EA EA201691327A patent/EA201691327A1/ru unknown
- 2013-03-05 NZ NZ629684A patent/NZ629684A/en unknown
- 2013-03-05 PT PT137572301T patent/PT2834241T/pt unknown
- 2013-03-05 WO PCT/US2013/029157 patent/WO2013134288A1/en not_active Ceased
- 2013-03-05 SG SG11201405446PA patent/SG11201405446PA/en unknown
- 2013-03-05 MD MDA20140100A patent/MD20140100A2/ro not_active Application Discontinuation
- 2013-03-05 EA EA201491473A patent/EA025407B1/ru unknown
- 2013-03-05 CA CA2864305A patent/CA2864305C/en active Active
- 2013-03-05 PL PL13757230T patent/PL2834241T3/pl unknown
- 2013-03-05 TW TW102107672A patent/TW201350486A/zh unknown
- 2013-03-05 EP EP13757230.1A patent/EP2834241B1/en active Active
- 2013-03-05 ES ES13757230T patent/ES2848273T3/es active Active
- 2013-03-05 US US13/786,222 patent/US8865730B2/en active Active
- 2013-03-05 EA EA201690461A patent/EA201690461A1/ru unknown
- 2013-03-05 CN CN201610547374.4A patent/CN106146506A/zh active Pending
- 2013-03-05 SI SI201331843T patent/SI2834241T1/sl unknown
- 2013-03-05 AR ARP130100721A patent/AR090253A1/es unknown
- 2013-03-05 KR KR1020147027588A patent/KR20140133590A/ko not_active Withdrawn
-
2014
- 2014-08-11 ZA ZA2014/05870A patent/ZA201405870B/en unknown
- 2014-08-26 PH PH12014501920A patent/PH12014501920A1/en unknown
- 2014-09-05 CL CL2014002358A patent/CL2014002358A1/es unknown
- 2014-09-12 CO CO14202424A patent/CO7071131A2/es unknown
- 2014-09-22 US US14/493,261 patent/US9469643B2/en active Active
- 2014-09-26 EC ECIEPI201420478A patent/ECSP14020478A/es unknown
- 2014-09-26 MA MA37379A patent/MA37379A1/fr unknown
- 2014-10-01 CR CR20140460A patent/CR20140460A/es unknown
-
2016
- 2016-03-04 JP JP2016042418A patent/JP2016104823A/ja active Pending
- 2016-09-06 US US15/257,053 patent/US10730879B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509537A5 (enExample) | ||
| KR102493854B1 (ko) | (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염 | |
| AU2018360853B2 (en) | Modulators of the integrated stress pathway | |
| JP2007521340A5 (enExample) | ||
| EP2776436B1 (en) | New compounds | |
| CN114401952A (zh) | 作为整合应激通路的调节剂的被取代的环烷基化合物 | |
| CN102574837B (zh) | 新的5-氟尿嘧啶衍生物 | |
| AU2018360847A1 (en) | Modulators of the integrated stress pathway | |
| TWI706951B (zh) | 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法 | |
| JPH0347157A (ja) | 殺生物性芳香族化合物、その合成および医薬としてのその使用 | |
| JP2011511011A5 (enExample) | ||
| EP3519398A1 (en) | Pyridine compound | |
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| JP2012504628A5 (enExample) | ||
| WO2019079649A1 (en) | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE | |
| RU2020111019A (ru) | Полиморфная форма tg02 | |
| JP4707393B2 (ja) | 抗癌化合物 | |
| JP2011527330A5 (enExample) | ||
| EP3454852A1 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| CN105985349B (zh) | 七元环小檗碱类似物及其药物组合物、制备方法和用途 | |
| JP2019514905A5 (enExample) | ||
| CN103304466A (zh) | 一种3-烷基取代吲哚类化合物的合成方法 | |
| CN101921223A (zh) | 吲哚-3-甲醇的合成方法 | |
| CN102838567A (zh) | 一种苯磺酰或苯甲酰哌嗪类化合物及其制备方法和用途 | |
| EP1966192B1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth |